Changes in benign prostatic hyperplasia management in Valencia: A real-world evidence analysis

被引:0
|
作者
Navarro-Perez, J. [1 ]
Alcina, E. Lopez [2 ]
Perez, J. Calabuig [3 ]
Munto, F. Brotons [4 ]
Martinez, A. [5 ]
Vallejo, L. [6 ]
Jimenez, J. [6 ]
机构
[1] Univ Valencia, Hosp Clin Univ Valencia, Ctr Invest Biomed Red Epidemiol & Salud Publ CIBER, Inst Invest Sanitaria INCLIVA, Valencia, Spain
[2] Consorcio Hosp Gen Univ Valencia, Serv Urol, Valencia, Spain
[3] Conselleria San Universal & Salud Publ, Serv Anal Sistemas Informac Sanitaria, Valencia, Spain
[4] Ctr Salud Trinitat, Valencia, Spain
[5] GlaxoSmithKline, Dept Med, Madrid, Spain
[6] GlaxoSmithKline, Dept Market Access, Madrid, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2024年 / 48卷 / 06期
关键词
Benign prostatic hyperplasia; Training program; Primary care; Real-world study; URINARY-TRACT SYMPTOMS; GUIDELINES;
D O I
10.1016/j.acuro.2023.11.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: A training program was developed to increase general practitioners' engagement in the optimal management of benign prostatic hyperplasia (BPH). The goal of this study was to evaluate changes in BPH management after the implementation of a training program. Material and methods: This observational retrospective cohort study was conducted between 2019 and 2020. Aggregated data were analyzed in 3 evaluation periods (2010, 2012 and 2015), addressing quality indicators for diagnosis, treatment, and treatment outcomes. Results: Overall, 118,795 patients who presented any data points were included. All quality indicators (number of IPSS and PSA determinations) increased between the first period and the last. Combination (alpha-blocker + 5-ARI) therapy was increasingly prescribed during the study periods whereas the proportion of prescriptions for single -agent alpha-blocker showed no significant differences among the periods analyzed. However, the total number of patients eligible for combination therapy who actually received this treatment was low in all periods (7.5, 17.9, and 20.1%, in 2010, 2012, and 2015, respectively). The outcome indicators revealed a decrease in referrals to the Urology unit mostly among newly diagnosed patients. Even though the proportion of patients who underwent BPH-related surgeries increased significantly from the first to the second period, the number of surgeries remained stable between the second and third periods. Conclusions: The training program had a generally positive impact on the management of BPH patients in primary care, but the overall study period may be insufficient to show an effect on some outcome indicators such as the number of surgeries. (c) 2024 The Authors. Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of AEU. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:461 / 469
页数:9
相关论文
共 50 条
  • [1] REAL-WORLD EVIDENCE OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN GERMANY
    Miernik, A.
    Gratzke, C.
    Suarez, R., I
    Fritzsche, J.
    Beyer, T.
    Habbig, B.
    Malka, V
    VALUE IN HEALTH, 2022, 25 (01) : S214 - S214
  • [2] APPLICATION OF REAL-WORLD EVIDENCE TO ASSESS OUTCOMES AFTER SURGICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA
    Orlowski, A.
    Kayes, O.
    VALUE IN HEALTH, 2018, 21 : S113 - S113
  • [3] Real-world evidence of patient perceptions and willingness to pay for a minimally surgical procedure for benign prostatic hyperplasia
    Rojanasarot, S.
    Cutone, B.
    Durand, K.
    Zorn, K. C.
    Chughtai, B.
    Bhojani, N.
    Elterman, D.
    EUROPEAN UROLOGY, 2022, 81 : S1077 - S1078
  • [4] UROLIFT VERSUS REZUM FOR BENIGN PROSTATIC HYPERPLASIA: A REAL-WORLD SINGLE-INSTITUTION ANALYSIS
    Chin, Chih Peng
    Garden, Evan
    Ravivarapu, Krishna
    Shukla, Devki
    Omidele, Olamide
    Levy, Micah
    Araya, Joseph Sewell
    Small, Alexander
    Kaplan, Steven
    Valenzuela, Robert
    Reddy, Avinash
    Marshall, Susan
    Motola, Jay
    Nobert, Craig
    Gupta, Mantu
    Palese, Michael
    JOURNAL OF UROLOGY, 2022, 207 (05): : E782 - E783
  • [5] Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain
    Minana, Bernardino
    Maria Molero, Jose
    Agra Rolan, Alfonso
    Tellez Martinez-Fornes, Miguel
    Cuervo Pinto, Rafael
    Lorite Mingot, David
    Carreno, Agata
    Manuel Palacios-Moreno, Juan
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (08)
  • [6] Real-world data comparing minimally invasive surgeries for benign prostatic hyperplasia
    Brendan L. Raizenne
    Xinyan Zheng
    Jialin Mao
    Kevin C. Zorn
    Ahra Cho
    Dean Elterman
    Naeem Bhojani
    Art Sedrakyan
    Bilal Chughtai
    World Journal of Urology, 2022, 40 : 1185 - 1193
  • [7] Real-world data comparing minimally invasive surgeries for benign prostatic hyperplasia
    Raizenne, Brendan L.
    Zheng, Xinyan
    Mao, Jialin
    Zorn, Kevin C.
    Cho, Ahra
    Elterman, Dean
    Bhojani, Naeem
    Sedrakyan, Art
    Chughtai, Bilal
    WORLD JOURNAL OF UROLOGY, 2022, 40 (05) : 1185 - 1193
  • [8] A real-world evidence study of interhospital variability in the surgical treatment of patients with benign prostatic hyperplasia: the REVALURO study
    Ivan, Povo Martin
    Alberto, Budia Alba
    Lluis, Peri Cusi
    Maurizio, D'Anna
    Jose Luis, Gutierrez Banos
    Francisco Javier, Vicente Prados
    Almudena, Sabio Bonilla
    Jaime, Garcia Herrero
    Esperanza, Torres Mingorance
    Pablo, Bretos Azcona
    Gabriela, Ojeda Arqueros
    Manuel, Gomez-Barrera
    Angel, Casado Miguel
    Alberto, de la Cuadra-Grande
    Emilio, Lopez Alcina
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025, 57 (03) : 775 - 784
  • [9] Real life practice in the management of benign prostatic hyperplasia
    Naderi, N
    Mochtar, CA
    de la Rosette, JJMCH
    CURRENT OPINION IN UROLOGY, 2004, 14 (01) : 41 - 44
  • [10] Real-World Use of Permixon® in Benign Prostatic Hyperplasia — Determining Appropriate Monotherapy and Combination Treatment
    Richard Perry
    Gary Milligan
    Peter Anderson
    Andrew Gillon
    Maren White
    Advances in Therapy, 2012, 29 : 538 - 550